A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

NCT00869895 | Completed Phase 1

• 1 other identifier: E7050-E044-101
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.

Conditions

Cancer

Keywords

Advanced solid tumors

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated Dose: the highest dose at which no more than 1 out of 6 patients experiences Dose Limiting Toxicity (DLT) during Cycle 1.

  Weekly assessments during the first 4 weeks of treatment.

Secondary Outcomes (4)

• DLTs and adverse events.

  Weekly assessments during the first 4 weeks of treatment for DLTs and throughout the study for AEs.

• Pharmacokinetics (blood and urine).

  Weekly assessments of blood during Cycle 1 and every 2 weeks for subsequent cycles and of urine on Day 1 of Cycles 1 and 2.

• Pharmacodynamics (blood).

  Weekly assessments during Cycle 1, every 2 weeks on Cycle 2, and on Day 1 of subsequent cycles.

• Best overall tumor response, duration of response and duration of stable disease assessed according to modified RECIST (Response Evaluation Criteria in Solid Tumors).

  At Screening, between Days 21 and 28 of every even cycle, and at the Final Visit.

Study Arms (1)

1

EXPERIMENTAL

Drug: E7050

Interventions

E7050 DRUG

Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years.
• Histologically and/or cytologically confirmed metastatic solid tumors, that have progressed after treatment with approved therapies, or for which there are no standard effective therapies available.
• Adequate bone marrow function.
• Adequate renal function.
• Adequate liver function.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Life expectancy \> 3 months.
• Be willing and able to comply with the study protocol, and can give written informed consent.
• At least one tumor lesion with diameter \>= 2 cm measurable according to Modified RECIST.

You may not qualify if:

• Any condition that may preclude oral intake or oral absorption, history of gastrointestinal malabsorption, or surgery involving gastro- and/or intestinal- anastomosis within 4 weeks prior to starting study drug.
• Untreated or unstable known primary or metastatic central nervous system (CNS) tumors (stability shown by contrast-enhanced computed tomography or magnetic resonance imaging scans at least 8 weeks apart, with the most recent scan obtained within 28 days prior to starting study treatment).
• Known human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infection or intercurrent illness (unrelated to tumor).
• Prior surgery, radiotherapy, chemotherapy, biologic therapy or investigational drugs within 4 weeks prior to starting study drug. Prior immunotherapy, hormonal, or molecular targeted therapy within 2 weeks prior to starting study treatment (except gonadorelin analogue therapy for prostate cancer is allowed). (All acute toxicities related to prior treatments should have resolved).
• Clinically significant cardiac impairment or unstable ischemic heart disease including a myocardial infarction within 6 months prior to starting study drug.
• Requiring therapeutic anti-coagulant therapy (prophylactic dose of heparin or low molecular weight heparin is allowed).
• Poorly controlled hypertension (defined as a change in hypertensive therapy within 3 months of starting study drug) or hypertension diagnosed at screening (defined as a repeat blood pressure measurement of 160/90 mmHg or higher).
• Perimenopausal women must have been amenorrheic for at least 12 months; otherwise a pregnancy test is required.
• Male patients must agree to use contraceptive methods (e.g., abstinence, or a double-barrier method \[e.g., condom + spermicide, condom + partner diaphragm with spermicide\]).
• History of any malignancy other than the present malignancy (except treated non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 5 years.

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (2)

Christie Hospital

Manchester, M20 4BX, United Kingdom

Location

Royal Marsden Hospital

Surrey, SM2 5PT, United Kingdom

Location

MeSH Terms

Conditions

Neoplasms

Interventions

N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Study Officials

• Wouter Hanekom

  Eisai Limited

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 25, 2009
• First Posted: March 26, 2009
• Study Start: March 1, 2009
• Primary Completion: August 1, 2012
• Last Updated: January 29, 2016

Record last verified: 2012-11

Locations

GB (2)